Last reviewed · How we verify
Imprimis Less Drops
Imprimis Less Drops is a compounded ophthalmic formulation designed to reduce ocular surface inflammation and provide symptomatic relief in dry eye disease.
Imprimis Less Drops is a compounded ophthalmic formulation designed to reduce ocular surface inflammation and provide symptomatic relief in dry eye disease. Used for Dry eye disease (keratoconjunctivitis sicca), Ocular surface inflammation.
At a glance
| Generic name | Imprimis Less Drops |
|---|---|
| Sponsor | Eye Center of North Florida |
| Drug class | Compounded ophthalmic anti-inflammatory/lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
This is a customized eye drop preparation compounded by Imprimis Pharmaceuticals for individual patients. The formulation typically contains anti-inflammatory and lubricating agents tailored to patient-specific needs. It is part of the 'Less Drops' line, which aims to minimize the number of daily instillations required while maintaining therapeutic efficacy.
Approved indications
- Dry eye disease (keratoconjunctivitis sicca)
- Ocular surface inflammation
Common side effects
- Ocular irritation
- Transient stinging or burning
- Conjunctival hyperemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imprimis Less Drops CI brief — competitive landscape report
- Imprimis Less Drops updates RSS · CI watch RSS
- Eye Center of North Florida portfolio CI